Severe and refractory chronic breathlessness is a common and burdensome symptom in patients with advanced life-limiting disease. Its clinical management is challenging because of the lack of effective interventions.
Aim:
To provide practice recommendations on the safe use of pharmacological therapies for severe chronic breathlessness.
Design:
Scoping review of (inter)national guidelines and systematic reviews. We additionally searched for primary studies where no systematic review could be identified. Consensus on the recommendations was reached by 75% approval within an international expert panel.
Data sources:
Searches in MEDLINE, Cochrane Library and Guideline International Network until March 2023. Inclusion of publications on the use of antidepressants, benzodiazepines, opioids or corticosteroids for chronic breathlessness in adults with cancer, chronic obstructive pulmonary disease, interstitial lung disease or chronic heart failure.
Results:
Overall, the evidence from eight guidelines, 14 systematic reviews and 3 randomised controlled trials (RCTs) on antidepressants is limited. There is low quality evidence favouring opioids in patients with chronic obstructive pulmonary disease, cancer and interstitial lung disease. For chronic heart failure, evidence is inconclusive. Benzodiazepines should only be considered for anxiety associated with severe breathlessness. Antidepressants and corticosteroids should not be used.
Conclusion:
Management of breathlessness remains challenging with only few pharmacological options with limited and partially conflicting evidence. Therefore, pharmacological treatment should be reserved for patients with advanced disease under monitoring of side effects, after optimisation of the underlying condition and use of evidence-based non-pharmacological interventions as first-line treatment.
JohnsonMJYorkeJHansen-FlaschenJ, et alTowards an expert consensus to delineate a clinical syndrome of chronic breathlessness. Eur Respir J2017; 49: 1–8.
2.
CurrowDCAbernethyAPAllcroftP, et alThe need to research refractory breathlessness. Eur Respir J2016; 47: 342–343.
3.
EcenarroPSIguiñizMITejadaSP, et alManagement of COPD in end-of-life care by spanish pulmonologists. COPD2018; 15: 171–176.
4.
MaddocksMLovellNBoothS, et alPalliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease. Lancet2017; 390: 988–1002.
5.
RockerGMSimpsonACHortonR.Palliative care in advanced lung disease: the challenge of integrating palliation into everyday care. Chest2015; 148: 801–809.
6.
HuiDBohlkeKBaoT, et alManagement of dyspnea in advanced cancer: ASCO guideline. J Clin Oncol2021; 39: 1389–1411.
7.
KrajnikMHepgulNWilcockA, et alDo guidelines influence breathlessness management in advanced lung diseases? A multinational survey of respiratory medicine and palliative care physicians. BMC Pulm Med2022; 22: 41.
8.
MunnZPetersMDJSternC, et alSystematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol2018; 18: 143.
9.
TriccoACLillieEZarinW, et alPRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med2018; 169: 467–473.
10.
McKinleyRKScheeleF.Do, don’t and don’t know: guidelines for medical education with a difference. Perspect Med Educ2015; 4: 275–276.
11.
HuiDMaddocksMJohnsonMJ, et alManagement of breathlessness in patients with cancer: ESMO clinical practice guidelines. ESMO Open2020; 5: e001038.
12.
AssayagDCampPGFisherJ, et alComprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Cana J Respir Crit Care Sleep Med2018; 2: 234–243.
13.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (ed). Palliativmedizin für Menschen mit einer nicht-heilbaren Krebserkrankung. Langversion 2.2. Stuttgart: Kohlhammer, 2020.
14.
LuckettTRobertsMSmithT, et alImplementing the battery-operated hand-held fan as an evidence-based, non-pharmacological intervention for chronic breathlessness in patients with chronic obstructive pulmonary disease (COPD): a qualitative study of the views of specialist respiratory clinicians. BMC Pulm Med2022; 22: 129.
15.
HutchinsonAAllgarVCohenJ, et alMixed-methods feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE): study findings. ERJ Open Res2022; 8: 1–13.
16.
YorkeJJohnsonMJPunnettG, et alRespiratory distress symptom intervention for non-pharmacological management of the lung cancer breathlessness-cough-fatigue symptom cluster: randomised controlled trial. BMJ Support Palliat Care2022; 13: e1181–e1190.
17.
GaertnerJFusi-SchmidhauserTStockS, et alEffect of opioids for breathlessness in heart failure: a systematic review and meta-analysis. Heart2023; 109: 1064–1071.
18.
BarnesHMcDonaldJSmallwoodN, et alOpioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev2016; 3: CD011008.
19.
EkströmMNilssonFAbernethyAA, et alEffects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc2015; 12: 1079–1092.
20.
LuoNTanSLiX, et alEfficacy and safety of opioids in treating cancer-related dyspnea: a systematic review and meta-analysis based on randomized controlled trials. J Pain Symptom Manage2021; 61: 198-210.e1.
21.
SimonSTKöskerogluPGaertnerJ, et alFentanyl for the relief of refractory breathlessness: a systematic review. J Pain Symptom Manage2013; 46: 874–886.
22.
Vargas-BermúdezACardenalFPorta-SalesJ.Opioids for the management of dyspnea in cancer patients: evidence of the last 15 years—a systematic review. J Pain Palliat Care Pharmacother2015; 29: 341–352.
23.
BajwahSRossJRPeacockJL, et alInterventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. Thorax2013; 68: 867–879.
24.
FelicianoJLWaldfogelJMSharmaR, et alPharmacologic interventions for breathlessness in patients with advanced cancer: a systematic review and meta-analysis. JAMA Netw Open2021; 4: e2037632.
25.
VerberktCAvan den Beuken-van EverdingenMHJScholsJMGA, et alRespiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. Eur Respir J2017; 50: 1701153.
26.
YamaguchiYSaif-Ur-RahmanKMNomuraM, et alOpioid prescription method for breathlessness due to non-cancer chronic respiratory diseases: a systematic review. Int J Environ Res Public Health2022; 19: 4907.
27.
EkströmMBajwahSBlandJM, et alOne evidence base; three stories: do opioids relieve chronic breathlessness?Thorax2018; 73: 88–90.
28.
BoydenJYConnorSROtolorinL, et alNebulized medications for the treatment of dyspnea: a literature review. J Aerosol Med Pulm Drug Deliv2015; 28: 1–19.
29.
NiciLMammenMJCharbekE, et alPharmacologic management of chronic obstructive pulmonary disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med2020; 201: e56–e69.
Lopez-CamposJLAlmagroPGómezJT, et alSpanish COPD guideline (GesEPOC) update: comorbidities, self-management and palliative care. Arch Bronconeumol2022; 58: T334–T344.
32.
DateKWilliamsBCohenJ, et alModified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol. ERJ Open Res2023; 9: 1–11.
33.
SobanskiPZAlt-EppingBCurrowDC, et alPalliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. Cardiovasc Res2020; 116: 12–27.
34.
EkströmMPBornefalk-HermanssonAAbernethyAP, et alSafety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ2014; 348: g445.
35.
VozorisNTPequenoPLiP, et alPredictors of opioid-related adverse pulmonary events among older adults with chronic obstructive pulmonary disease. Ann Am Thorac Soc2020; 17: 965–973.
36.
VozorisNTO‘DonnellDEGillSS.Opioids and adverse outcomes in elderly chronic obstructive pulmonary disease patients. Eur Respir J2016; 48: 1818.
37.
SimonSTHigginsonIJBoothS, et alBenzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev2016; 10: CD007354.
38.
BreilmannJGirlandaFGuaianaG, et alBenzodiazepines versus placebo for panic disorder in adults. Cochrane Database Syst Rev2019; 3: CD010677.
39.
SimonSTMoriMEkströmM, et alShould benzodiazepines be used for reducing dyspnea in patients with advanced illnesses?J Pain Symptom Manage2023; 65: e219–e223.
40.
SimonSTPralongARadbruchL, et alThe palliative care of patients with incurable cancer. Dtsch Arztebl Int2020; 116: 108–115.
BajwahSDaviesJMTanashH, et alSafety of benzodiazepines and opioids in interstitial lung disease: a national prospective study. Eur Respir J2018; 52: 1801278.
43.
AmbrosinoNFracchiaC.Strategies to relieve dyspnoea in patients with advanced chronic respiratory diseases: a narrative review. Pulmonology2019; 25: 289–298.
HaywoodADucJGoodP, et alSystemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. Cochrane Database Syst Rev2019; 2: CD012704.
46.
RaghuGAnstromKJKingTE, et alPrednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med2012; 366: 1968–1977.
47.
HuiDPuacVShelalZ, et alEffect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol2022; 23: 1321–1331.
48.
HigginsonIJBrownSTOluyaseAO, et al. Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial. Lancet Respir Med. Prepublished September 09, 2024, DOI: 10.1016/S2213-2600(24)00187-5.
49.
CurrowDCEkströmMLouwS, et alSertraline in symptomatic chronic breathlessness: a double blind, randomised trial. Eur Respir J2019; 53: 1–9.
50.
HigginsonIJWilcockAJohnsonMJ, et alRandomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). Thorax2020; 75: 176–179.
51.
WeingärtnerVScheveCGerdesV, et alCharacteristics of episodic breathlessness as reported by patients with advanced chronic obstructive pulmonary disease and lung cancer: Results of a descriptive cohort study. Palliat Med2015; 29: 420–428.
52.
WeingärtnerVBauseweinCHigginsonIJ, et alCharacterizing episodic breathlessness in patients with advanced disease. J Palliat Med2013; 16: 1275–1279.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
